19-Apr-2024
No headlines found.
Globe Newswire (Sat, 23-Mar 2:01 PM ET)
PRNewswire (Tue, 19-Mar 3:55 PM ET)
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
Globe Newswire (Tue, 19-Mar 10:15 AM ET)
Globe Newswire (Tue, 19-Mar 4:00 AM ET)
Globe Newswire (Mon, 18-Mar 12:30 PM ET)
Business Wire (Sun, 17-Mar 8:00 PM ET)
Globe Newswire (Sat, 16-Mar 9:00 PM ET)
Globe Newswire (Fri, 15-Mar 5:48 PM ET)
PRNewswire (Fri, 15-Mar 5:45 AM ET)
Globe Newswire (Thu, 14-Mar 11:30 AM ET)
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Allovir trades on the NASDAQ stock market under the symbol ALVR.
As of April 19, 2024, ALVR stock price climbed to $0.75 with 324,654 million shares trading.
ALVR has a beta of 2.41, meaning it tends to be more sensitive to market movements. ALVR has a correlation of 0.04 to the broad based SPY ETF.
ALVR has a market cap of $86.17 million. This is considered a Micro Cap stock.
In the last 3 years, ALVR stock traded as high as $26.41 and as low as $.62.
The top ETF exchange traded funds that ALVR belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
ALVR stock has underperformed the market in the last year with a return of -80.5%, while SPY returned +21.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ALVR shares. However, ALVR has outperformed the market in the last 3 month and 2 week periods, returning +10.3% and +0.4%, while SPY returned +3.0% and -4.5%, respectively. This indicates ALVR has been having a stronger performance recently.
ALVR support price is $.71 and resistance is $.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALVR stock will trade within this expected range on the day.